Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries

摘要

Latin American countries represents a large fraction of patients who are treated for multiple myeloma in the world and difficulties of access to new agents and real-world practice are important issues. In this study, we explore areas that impact the availability of anti-multiple myeloma drugs such as health care systems, approval times, coverage of new agents, old drugs, use of generics, and the first-line treatments in 16 nations.